Issue Date: February 3, 2014
Particle Sciences Joins With Hapten
Hapten Sciences and Particle Sciences are working together to move Hapten’s poison ivy, oak, and sumac therapy into clinical trials. According to Memphis-based Hapten, its injectable small-molecule therapy acts like a vaccine to lessen or eliminate contact dermatitis caused by exposure to urushiol oil in the plants. Particle Sciences will manufacture the therapy, which contains urushiol derivatives, for Phase I/II clinical studies scheduled for this year.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society